Iressa Gets Narrowed Indication Instead Of Withdrawal: New Model For FDA?

FDA's decision to narrow the indication for AstraZeneca's Iressa rather than withdraw the drug could be seen as a model for future products approved under Subpart H that fail in confirmatory trials